STOCK TITAN

LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock - LFMDP STOCK NEWS

Welcome to our dedicated page for LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock news (Ticker: LFMDP), a resource for investors and traders seeking the latest updates and insights on LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock stock.

LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (symbol: LFMDP) is backed by a company that offers a comprehensive telemedicine solution connecting physicians, medical providers, pharmacists, and patients worldwide. Their platform is HIPAA-compliant and encrypted, allowing for secure interactions and management of medical conditions. In addition to telehealth services, they also provide mobile diagnostic telehealth equipment and sell nutritional supplements and over-the-counter products. With a focus on virtual primary care, LifeMD is committed to providing accessible, high-quality healthcare services.

Rhea-AI Summary
LifeMD, Inc. (LFMD) announced participation in multiple investor conferences and a webinar to discuss GLP-1s. CEO Justin Schreiber will be presenting at various events to engage with investors and analysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
conferences
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) will participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13-14, 2024, at the Cliff Lodge in Snowbird, Utah. The company will hold one-on-one meetings during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
conferences
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) will participate in the Maxim Group 2024 Healthcare IT Virtual Conference on January 24-25, 2024. The company's management will engage in a virtual fireside chat and one-on-one meetings, offering investors an opportunity to engage with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
News
Rhea-AI Summary
LifeMD, Inc. (LFMD) expects revenue between $195 and $205 million, a 31% to 38% increase over 2023 guidance. Adjusted EBITDA is expected to be between $18 and $22 million, a 71% to 110% increase over the midpoint of 2023 guidance. The company also anticipates positive full-year free cash flow with estimated year-end 2023 cash exceeding $30 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.97%
Tags
none
-
Rhea-AI Summary
LifeMD, Inc. (Nasdaq: LFMD) authorizes a cash dividend of $0.5546875 per share for its 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP), payable on January 15, 2024, to holders of record on January 5, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
dividends
-
Rhea-AI Summary
LifeMD, Inc.TM (Nasdaq: LFMD) announced a strategic alliance with Medifast (NYSE: MED) to integrate LifeMD’s telehealth platform and GLP-1 offering for medically qualified patients with OPTAVIA Coach-guided, healthy lifestyle solution. Medifast has invested $20 million, including a $10 million payment in support of the collaboration and a $10 million purchase of LifeMD common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.42%
Tags
partnership
Rhea-AI Summary
LifeMD, Inc. (LFMD) to Participate in RWJBarnabas Health Telehealth Symposium, Showcasing the Role of Telehealth in Quality Patient Care
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.89%
Tags
conferences
-
Rhea-AI Summary
LifeMD, Inc. (LFMD) to participate in upcoming investor conferences and panel discussions. CEO Justin Schreiber to discuss GLP-1s at Cantor Fitzgerald panel and digital health at BTIG forum. Sidoti's Small-Cap Virtual Conference to feature corporate overview and one-on-one investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
conferences
-
Rhea-AI Summary
LifeMD, Inc. (Nasdaq: LFMD) reported a 23% year-over-year revenue increase to $38.6 million, with record revenues for telehealth and WorkSimpli. Adjusted EPS was $0.08 per share, compared to a loss of $0.03 in the previous year. Weight Management revenue more than quadrupled, and telehealth subscribers grew 22% to a record 207,000 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
Rhea-AI Summary
LifeMD (NASDAQ: LFMD) achieved 855% revenue growth, ranking 166 on the Deloitte Technology Fast 500™. The growth is attributed to the differentiated, end-to-end care platform and affiliated medical group, supporting offerings like the LifeMD Weight Management Program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
none

FAQ

What is the current stock price of LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP)?

The current stock price of LifeMD 8.875% Series A Cumulative Perpetual Preferred Stock (LFMDP) is $21.866 as of November 4, 2024.

What does LifeMD, Inc. offer?

LifeMD offers a comprehensive telemedicine solution connecting physicians, medical providers, pharmacists, and patients worldwide.

Is LifeMD's platform secure?

Yes, LifeMD's platform is HIPAA-compliant and all interactions are encrypted for security.

What products does LifeMD sell?

In addition to telehealth services, LifeMD sells nutritional supplements and over-the-counter products.

What is the focus of LifeMD's services?

LifeMD is focused on providing virtual primary care to make high-quality healthcare accessible for all.

How does LifeMD contribute to the healthcare industry?

LifeMD's telemedicine platform and services aim to improve patient outcomes and provide more convenient access to healthcare.

LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock

Nasdaq:LFMDP

LFMDP Rankings

LFMDP Stock Data

1.40M
Health Information Services
Services-offices & Clinics of Doctors of Medicine
Link
United States of America
NEW YORK